Alzheimer’s disease
|
Lithium
|
Various models
|
Regulation of inositol monophosphatase, GSK-3β, and mTOR
|
[161]
|
Hydroxyurea
|
APP/PS1 mice
|
Augmentation of the expression of LC3
|
[162]
|
Atorvastatin
|
Aβ1–42- SH-SY5Y
|
Elevation of the expression of sestrins and LC3-II, alleviation of sirtuins and TPP1
|
[163]
|
Ferric-Tannic nanoparticles
|
In vitro
|
activation of lysosome
|
[164]
|
Curcumin
|
APP/PS1 double transgenic AD mice
|
Inhibition of PI3K/Akt/mTOR, an increase of LC3I/II and Beclin1 expression
|
[165]
|
Berberine
|
Three × Tg-AD mice
|
Augmentation of LC3-II, Beclin-1, hVps34, and Cathepsin-D
|
[166]
|
Berberine and Curcumin
|
Aβ1-42-AD mice
|
Augmentation of AMPKα phosphorylation and cell autophagy
|
[65]
|
Resveratrol
|
Aβ1–42-induced AD-PC12
|
Activation of mitophagy due to the abrogation of oxidative stress
|
[167]
|
Geniposide
|
APP/PS1 mice
|
downregulation of mTOR
|
[168]
|
Polydatin
|
Aβ-induced neuron cytotoxicity
|
activation of AMPK/mTOR pathway
|
[169]
|
Melatonin
|
AAV-hTauP301L viral vectors and okadaic acid-Tauopathy, mice and human brain tissue
|
improvement of the autophagy markers comprising p62, LAMP1, and LC3
|
[170]
|
α-Tocopherol
|
Aβ-SH-SY5Y
|
Regulation of cathepsin-B, -L, -D, syntaxin 17, GABA type A receptor-associated protein, GABA type A receptor-associated protein-like 1; ATG3, ATG4A, ATG4B, myotubularin related protein 3, UV radiation resistance-associated, autophagy and Beclin 1 regulator 1, vacuole membrane protein 1, WDrepeat domain, phosphoinositide interacting 1, WDrepeat domain, phosphoinositide interacting 2, unc-51 like autophagy activating kinase 2
|
[171]
|
Oleuropein aglycone
|
Aβ-AD mice, SH-SY5Y
|
Induction of AMPK/ULK1, inhibition of mTOR
|
[172, 173]
|
Garcinol
|
Acrylamide-brain of zebrafish larvae
|
Regulation of cathepsin-B
|
[174]
|
Carnosic acid
|
Aβ 1–42- SH-SY5Y
|
Increase LC3-II/I ratio, decrease SQSTM1(p62)
|
[175]
|
β-asarone
|
Aβ, PC12 cells
|
Alleviation of autophagy occurred via Akt/mTOR signaling pathway
|
[176]
|
Euxanthone
|
Aβ1-42-PC12
|
Augmentation of LC3-II and Beclin1, alleviation of p62
|
[177]
|
Oleocanthal
|
TgSwDI mice
|
Activation of AMPK/ ULK1 pathway
|
[178]
|
Ganoderma lucidum
|
MPTP-induced PD in mice
|
Elevation of NIX expression, decrease of LC3-II/LC3-I ratio, regulation of AMPK, mTOR, and ULK1
|
[179]
|
Parkinson’s disease
|
Metformin
|
In vitro and in vivo
|
Activation of AMPK and inhibition of α-synuclein
|
[180]
|
Sulforaphane
|
Rotenone-mice, SH-SY5Y
|
Decrease expression of LC3-II
|
[181]
|
Morphine (low dose)
|
6-OHDA-SH-SY5Y and rats
|
Augmentation of LC3-II, alleviation of p62
|
[182]
|
Manganese nanoparticle
|
N27 dopaminergic neuronal cells
|
Improvement of Beclin 1 and LC3
|
[183]
|
α-Arbutin
|
Rotenone-induced PD, SH-SY5Y, drosophila
|
Modulation of AMPK/p62
|
[184]
|
Polydatin
|
Rotenone or Parkin deficiency-SH-SY5Y
|
Promotion of ATG5 in a parkin-independent autophagy manner
|
[185]
|
Glycyrrhizic acid
|
6-OHDA and corticosterone-induced PD in SH-SY5Y
|
Attenuation of α-Syn and p-S1292-LRRK2 proteins expression, upregulation of LC3B II/I and Beclin-1
|
[186]
|
α-lipoic acid
|
6-OHDA-SH-SY5Y cells
|
blockade AMPK/mTOR signaling pathway
|
[187]
|
Icariin
|
Rotenone-PC12 cells
|
Regulation of LC3-II, Beclin1, p62
|
[188]
|
β-amyrin
|
6-OHDA- Caenorhabditis elegans
|
Regulation of LGG-1
|
[189]
|
kaempferol
|
Rotenone- SH-SY5Y
|
Increase the expression of LC3-II
|
[190]
|
Huntington’s disease
|
Tolfenamic acid
|
transgenic R6/1 mice
|
Increase LC3-II/LC3-I ratio, decrease expression of p62
|
[191]
|
Liraglutide
|
mHTT- SK-N-MC cells
|
Upregulation of the phosphorylation of Thr172-AMPK and LC3-II
|
[192]
|
Trehalose
|
skin biopsies of HD patients
|
Increase LC3 and LAMP2-A levels
|
[193]
|
Resveratrol
|
polyQ-Htt- SH-SY5Y
|
restoring ATG4 level, allowing the LC3 lipidation, facilitating polyQ-Htt degradation
|
[194]
|
Rutin
|
Caenorhabditis elegans
|
Autophagy by activation of protein degradation
|
[195]
|
Amyotrophic lateral sclerosis
|
Riluzole
|
HeLa cells
|
Increase the amount of HSF1 regarding the chaperone-mediated autophagy
|
[196]
|
p-Coumaric Acid
|
SOD1mut- N2a cells
|
increased the level of LC3-II, decrease the protein level of p62
|
[197]
|
Cerebral ischemia
|
Ulinastatin
|
A variety of models
|
Inhibition of neuronal autophagy
|
[198]
|
Tanshinone IIA
|
OGD/R- HT-22 cells
|
Activation of PI3K/Akt/mTOR pathway
|
[112]
|
Resveratrol
|
cerebral ischemia rats
|
Increase expression of LC3II
|
[199]
|
Gabapentin
|
middle cerebral artery occlusion-rats
|
Regulation of the PI3K/Akt/mTOR signaling pathway
|
[200]
|
Melatonin
|
I/R-rats, OGD/R-PC12 cells
|
Reduction of LC3II/LC3I, an increase of p62
|
[201]
|
Lycium barbarum polysaccharide
|
OGD/R- primary hippocampal neurons
|
Activation of PI3K/Akt/mTOR pathway
|
[202]
|
Tetrahydroxystilbene glucoside
|
middle cerebral artery occlusion-mice
|
Elevation of Beclin 1 and the LC3BII/I ratio
|
[203]
|
Shengmai
|
Cerebral I/R injury-mice
|
modulation of the AMPK, mTOR, and JNK pathways, inhibition of Beclin1 and LC3
|
[204]
|
Esculetin
|
transient bilateral typical carotid artery occlusion -treated mice
|
Regulation of Bnip3, Beclin1, Pink1, parkin, and the LC-3 II/I ratio
|
[205]
|
Luteolin
|
MCAO rat model
|
Regulation of SIRT3/AMPK/mTOR Signaling Pathway
|
[106]
|
Chronic Cerebral Hypoperfusion
|
Resveratrol
|
CCH-rats
|
Regulation of AKT/mTOR Signaling
|
[206]
|
Spinal Cord Injury
|
Omega-3 fatty acids
|
Rodent models
|
Increase of LC3-II expression, reduction of p38 MAPK expression
|
[207]
|
Calcitriol
|
laminectomy and spinal cord compression injury-rats
|
Augmentation of LC3-II and Beclin1, alleviation of p62
|
[208]
|
Spinocerebellar ataxia
|
Caffeic acid and resveratrol
|
mutant ataxin-3-SK-N-SH-MJD78 cells, Drosophila
|
Upregulation of p62 expression
|
[209]
|
lactulose and melibiose
|
SCA3 ATXN3/Q75-GFP cell model
|
Regulation of autophagy
|
[210]
|
Neurotoxicity
|
Methylone and MDPV
|
β-keto amphetamines-SH-SY5Y cells
|
Increase expression of LC3-II
|
[154]
|